Eli Lilly (NYSE:LLY | LLY Price Prediction) has quietly transformed itself into the first pharmaceutical company ever valued above $1 trillion, and yet the market may still be underpricing what comes next. Retatrutide, orforglipron, and a stacked oncology and neuroscience bench point to a growth runway that our proprietary model believes justifies a materially higher stock price over the next twelve months.
Our 24/7 Wall St. price target for Eli Lilly is $1,415.89, implying 19.67% upside from the current $1,183.16 quote. The recommendation is buy at 90% confidence. The model combines accelerating earnings, defensive beta, and pipeline blockbuster optionality.
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $1,183.16 |
| 24/7 Wall St. Price Target | $1,415.89 |
| Upside | 19.67% |
| Recommendation | BUY |
| Confidence Level | 90% |
A Trillion-Dollar Milestone, Then a Cool-Off
Lilly became the first pharmaceutical firm worth $1 trillion in late May, and shares are up 69.79% over the past year and 10.63% year to date. The stock is down 3.82% over the past week and sitting about 5% below the 52-week high of $1,247.66.
That pullback follows a Q2 report that was one of the cleanest earnings reports in large-cap pharma this cycle: revenue of $22.974 billion (up 47.67%), EPS of $8.38 beating expectations, and management raising FY26 revenue guidance to $85 to $87 billion.
The Case for $1,600+
The bull scenario points to $1,627.17, or 37.53% upside. Retatrutide, the triple GLP-1/GIP/glucagon agonist, produced weight loss approaching bariatric surgery levels across three positive Phase 3 trials, with a BLA submission planned for Q1 2027. AJMC called it a “trillion-dollar drug”, defensible given Lilly already owns roughly 6 out of 10 U.S. obesity prescriptions.
Foundayo, the only oral GLP-1 approved for anytime dosing, jumped from 8,000 to 36,000 prescribers in a single quarter. Add in the Medicare GLP-1 Bridge Program covering 20 million eligible Americans at $50 per month, and the analyst consensus target of $1,310.90 looks conservative.
What Could Go Wrong
The bear case pins fair value at $1,174.96, essentially flat. Risks include U.S. realized prices falling roughly 9% excluding rebate adjustments, Novo Nordisk competing for share, and manufacturing capacity constraints.
The Q2 tax rate spiked to 23.3% because of $2.78 billion in IPR&D charges from four acquisitions. Insider activity has skewed to net selling across 14 recent transactions. The IPR&D drag reflects aggressive pipeline building (Orna, Ajax, Centessa, Kelonia), and gross margin expanded to 85.8%.
How Lilly Compares to Novo Nordisk and Merck
Novo Nordisk (NYSE:NVO) trades at a forward P/E of just 14 with quarterly revenue growth of only 2.1% and earnings contracting 20.6% year over year. Lilly’s premium multiple is earned.
Merck (NYSE:MRK) offers a useful big-pharma contrast. Merck’s forward P/E is 50, with revenue growth of only 5.1% and EPS growth of negative 19.3%. Lilly’s 32x forward earnings paired with 47.67% revenue growth compares favorably on a growth-adjusted basis.
| Company | Forward P/E | Revenue Growth YoY |
|---|---|---|
| Eli Lilly | 32 | 47.67% |
| Novo Nordisk | 14 | 2.1% |
| Merck | 50 | 5.1% |
Eli Lilly Price Prediction 2026-2030
The 24/7 Wall St. model output is a buy rating at 90% confidence, with a price target of $1,415.89. Retatrutide is the tipping factor. If the BLA lands on time and the label spans obesity, sleep apnea, and osteoarthritis, the bull scenario at $1,627 becomes the base case. The thesis weakens if U.S. pricing erosion accelerates past 15% or Novo delivers a surprise oral formulation win.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $1,415.89 |
| 2027 | $1,585 |
| 2028 | $1,760 |
| 2029 | $1,910 |
| 2030 | $2,054.78 |
These projections assume Lilly executes on retatrutide’s launch and continues expanding Foundayo internationally. Significant upside or downside could result from GLP-1 competitive dynamics and U.S. drug-pricing policy.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks